Effect of a CCK-1R Agonist on Food Intake in Humans

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa

NCT00308776

Bulimia Nervosa Eating Disorders

TERMINATED NA

Treatment of Bulimia Nervosa in a Primary Care Setting

NCT00009178

Bulimia Nervosa

COMPLETED NA

Oral Naltrexone In Pediatric Eating Disorders

NCT05073679

Anorexia Nervosa/Bulimia Anorexia in Adolescence Anorexia Nervosa, Atypical +6 more

TERMINATED PHASE2/PHASE3

The Development of an Eating Laboratory for Overweight Adolescents

NCT00764127

Adolescent Obesity

COMPLETED

FDA Approved Medication to Reduce Binge Eating and/or Purging

NCT02553824

Binge Eating Disorder Bulimia Nervosa

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study tests the hypothesis that an oral CCK antagonist GSKI181771X will reduce the size of a binge meal. It was intended to study the effects of increasing doses on antagonist on normal individuals to find an effective dose in a non-binge meal before moving to a binge meal. Once the effects of the antagonist on a binge meal were found, the compound would be used on patients with bulimia nervosa. However, the product expired and more was not available before the patients were tested. Data are presented for the normal participants who were instructed to eat normally, followed by a group that was instructed to binge eat. Comparisons were made between groups with different instructions and between binge and normal meals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bulimia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 'Instructions to eat normally'

'Instructions to eat normally' Placebo 1 mg dose

Group Type PLACEBO_COMPARATOR

Instructions to eat normally

Intervention Type BEHAVIORAL

Subjects will be instructed to eat normally and will also be given either drug or placebo

Placebo

Intervention Type DRUG

Drug one trial vs placebo

2 'Instructions to eat normally'

'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'

Group Type ACTIVE_COMPARATOR

GSKI181771X (CCK-1R agonist)

Intervention Type DRUG

Drug one trial vs placebo

Instructions to eat normally

Intervention Type BEHAVIORAL

Subjects will be instructed to eat normally and will also be given either drug or placebo

3 'Instructions to eat normally'

'Instructions to eat normally' 2 mg placebo

Group Type PLACEBO_COMPARATOR

Instructions to eat normally

Intervention Type BEHAVIORAL

Subjects will be instructed to eat normally and will also be given either drug or placebo

Placebo

Intervention Type DRUG

Drug one trial vs placebo

4 'Instructions to eat normally'

'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'

Group Type ACTIVE_COMPARATOR

GSKI181771X (CCK-1R agonist)

Intervention Type DRUG

Drug one trial vs placebo

Instructions to eat normally

Intervention Type BEHAVIORAL

Subjects will be instructed to eat normally and will also be given either drug or placebo

5 'Instructions to eat normally'

'Instructions to eat normally' 4 mg placebo

Group Type PLACEBO_COMPARATOR

Instructions to eat normally

Intervention Type BEHAVIORAL

Subjects will be instructed to eat normally and will also be given either drug or placebo

Placebo

Intervention Type DRUG

Drug one trial vs placebo

6 'Instructions to eat normally'

'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'

Group Type ACTIVE_COMPARATOR

GSKI181771X (CCK-1R agonist)

Intervention Type DRUG

Drug one trial vs placebo

Instructions to eat normally

Intervention Type BEHAVIORAL

Subjects will be instructed to eat normally and will also be given either drug or placebo

7 Instructions to binge eat

Instructions to binge eat 4 mg placebo

Group Type PLACEBO_COMPARATOR

Instructions to binge eat

Intervention Type BEHAVIORAL

Subjects will be instructed to binge eat and will also be given either drug or placebo

Placebo

Intervention Type DRUG

Drug one trial vs placebo

8 Instructions to binge eat

Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'

Group Type ACTIVE_COMPARATOR

GSKI181771X (CCK-1R agonist)

Intervention Type DRUG

Drug one trial vs placebo

Instructions to binge eat

Intervention Type BEHAVIORAL

Subjects will be instructed to binge eat and will also be given either drug or placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSKI181771X (CCK-1R agonist)

Drug one trial vs placebo

Intervention Type DRUG

Instructions to binge eat

Subjects will be instructed to binge eat and will also be given either drug or placebo

Intervention Type BEHAVIORAL

Instructions to eat normally

Subjects will be instructed to eat normally and will also be given either drug or placebo

Intervention Type BEHAVIORAL

Placebo

Drug one trial vs placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GSKI181771X

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both controls and patients will be female, 18 to 45 years old, and within 80-120% of ideal body weight (Metropolitan Life Insurance, 1983). Inclusion and exclusion will be evaluated using the following guidelines:

Normal Controls:

* No current or past psychiatric illness
* No history of binge eating or vomiting
* 80-120% ideal weight
* Of non-childbearing potential (i.e. physiologically incapable of becoming pregnant or surgically sterile)
* If of childbearing potential, willing to use an acceptable method of birth-control (please see list in "Exclusion" section)

Patients with Bulimia Nervosa:

* DSM-IV (diagnostic statistical manual - American Psychiatric Association) criteria for bulimia nervosa
* Duration of illness \> 1 year
* Purging after binges via self-induced vomiting

Exclusion Criteria

Normal Controls:

* Significant medical illness: CBC, Chem-1, serum electrolytes (sodium, potassium, chloride, CO2), glucose, BUN (blood urea nitrogen), creatinine, Alk Phos, ALT (SGPT), AST (SGOT), LDH, total bilirubin, total protein, albumin, globulin, A/G ratio, calcium, phosphorus, uric acid, cholesterol, triglyceride
* ALT outside of upper limit of normal: Chem-1
* History of gallstones, pancreatitis or cholecystitis
* Current medication
* Hypersensitivity to benzodiazepines (contraindication in DCSI v02, 1-March-2006)
* Drug or alcohol abuse in last 3 mts
* Pregnancy
* Unable or unwilling to use highly effective methods of contraception for the duration of the study until an insignificant amount of the investigational product remains in the subject (i.e. at least 5 terminal phase half-lives). Examples of highly effective methods of contraception are:

* Implants of levonorgestrel, or
* Injectable progestogen, or
* Oral birth control pills for at least 3 monthly cycles prior to administration of study drug + continuation for 24 hrs after last dose of study drug, or
* Double-barrier method (e.g. condom, diaphragm) with spermicide

Note-Significant medical illness is any illness requiring continued care, i.e. chronic medication. Examples include hypertension, diabetes, and systemic lupus erythematosis. Subjects with seasonal allergies or occasional urinary tract infections will be included.

Patients with Bulimia Nervosa:

* Same as controls

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes